US20120152743A1 - Method for electroeluting genetic material from dried samples - Google Patents
Method for electroeluting genetic material from dried samples Download PDFInfo
- Publication number
- US20120152743A1 US20120152743A1 US12/972,236 US97223610A US2012152743A1 US 20120152743 A1 US20120152743 A1 US 20120152743A1 US 97223610 A US97223610 A US 97223610A US 2012152743 A1 US2012152743 A1 US 2012152743A1
- Authority
- US
- United States
- Prior art keywords
- solid medium
- dna
- genetic material
- sample
- fixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 94
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 55
- 239000007787 solid Substances 0.000 claims abstract description 154
- 239000012472 biological sample Substances 0.000 claims abstract description 34
- 239000000126 substance Substances 0.000 claims abstract description 19
- 108020004414 DNA Proteins 0.000 claims description 107
- 239000000523 sample Substances 0.000 claims description 88
- 238000001962 electrophoresis Methods 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229920002678 cellulose Polymers 0.000 claims description 15
- 239000001913 cellulose Substances 0.000 claims description 15
- 230000008439 repair process Effects 0.000 claims description 15
- 238000002791 soaking Methods 0.000 claims description 9
- 102000012410 DNA Ligases Human genes 0.000 claims description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 108010061982 DNA Ligases Proteins 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 7
- 208000035657 Abasia Diseases 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 239000012038 nucleophile Substances 0.000 claims description 4
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 2
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 2
- 108010010677 Phosphodiesterase I Proteins 0.000 claims description 2
- 230000001915 proofreading effect Effects 0.000 claims description 2
- 108010068698 spleen exonuclease Proteins 0.000 claims description 2
- 238000013519 translation Methods 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims 2
- 108010042407 Endonucleases Proteins 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 description 38
- 239000000499 gel Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000007853 buffer solution Substances 0.000 description 15
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 15
- 239000010931 gold Substances 0.000 description 15
- 229910052737 gold Inorganic materials 0.000 description 15
- 230000033616 DNA repair Effects 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 210000002307 prostate Anatomy 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 239000003599 detergent Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 238000001502 gel electrophoresis Methods 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 7
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 229960001484 edetic acid Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007984 Tris EDTA buffer Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 3
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 2
- 102000010719 DNA-(Apurinic or Apyrimidinic Site) Lyase Human genes 0.000 description 2
- 108010063362 DNA-(Apurinic or Apyrimidinic Site) Lyase Proteins 0.000 description 2
- 108010036364 Deoxyribonuclease IV (Phage T4-Induced) Proteins 0.000 description 2
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007998 bicine buffer Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- SFRDXVJWXWOTEW-UHFFFAOYSA-N 2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)CO SFRDXVJWXWOTEW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004614 Process Aid Substances 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- -1 bicine Chemical class 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 150000007971 urates Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
Definitions
- the subject matter disclosed herein relates to a solid medium for use in the storage of genetic material from biological samples and more particularly to methods to electroelute genetic material from the biological samples directly from the solid medium.
- Various facilities include storage systems for large collections of genetic material (e.g., DNA) collected from a wide range of sources (e.g., human blood, cell lines, etc.).
- the genetic material is stored in a safe, convenient, and minimally labor intensive manner within these storage systems for later analysis.
- solid media such as Whatman® FTA® substrates, are used to store genetic material from various biological samples, such as tissues or cells.
- extracting genetic material from the solid media involves additional labor, sometimes intensive labor when dealing with numerous samples.
- extraction of genetic material may include either using detergents or incubating the solid media at high temperatures. The detergent may interfere with analysis of the genetic material, thus additional labor is required to remove the detergent. Also, the higher temperatures may fragment the genetic material.
- there is a need to reduce the work required to extract genetic material, while also minimizing the fragmentation of the genetic material.
- a method for extracting genetic material from a biological sample stored on a solid medium includes obtaining the solid medium, wherein the biological sample is applied on the solid medium, and the solid medium includes chemicals that lyzed the biological sample and preserved the genetic material. The method also includes electroeluting the genetic material directly from the solid medium to a subsequent medium.
- a method for extracting genetic material from a fixed tissue sample stored on a solid medium includes applying at least a portion of the fixed tissue sample to the solid medium, wherein the solid medium includes chemicals that can lyse the cells or preserve the genetic material. The method further includes electroeluting the genetic material directly from the solid medium to a subsequent medium.
- a method for extracting DNA from a biological sample stored on a cellulose-based paper includes obtaining the cellulose-based paper, wherein the biological sample is applied on the cellulose-based paper, and the cellulose based paper includes chemicals that lyse the biological sample and preserve the DNA.
- the method also includes electroeluting DNA directly from the cellulose-based paper into an electrophoresis gel.
- FIG. 1 is a flow chart illustrating a method for extracting genetic material from a biological sample stored on a solid medium in accordance with aspects of the present disclosure
- FIG. 2 depicts a SYBR® Gold stained electrophoresis gel of DNA electroeluted from solid media using pulsed-field gel electrophoresis in accordance with aspects of the present disclosure
- FIG. 3 depicts a SYBR® Gold stained electrophoresis gel of DNA electroeluted from solid media using alkaline gel electrophoresis in accordance with aspects of the present disclosure
- FIG. 4 is a flow chart illustrating a method for extracting genetic material from a fixed tissue sample stored on a solid medium in accordance with aspects of the present disclosure
- FIG. 5 depicts a SYBR® Gold stained electrophoresis gel, using a vertical polyacrylamide gel electrophoresis (PAGE) system, of multiplex PCR amplification of DNA that has been extracted from a human prostate sample fixed in formalin and applied to Whatman® FTA® paper;
- PAGE vertical polyacrylamide gel electrophoresis
- FIG. 6 depicts a SYBR® Gold stained electrophoresis gel of DNA electroeluted from solid media using native gel electrophoresis in accordance with aspects of the present disclosure
- FIG. 7 depicts a SYBR® Gold stained electrophoresis gel of DNA electroeluted from solid media using native gel electrophoresis in accordance with aspects of the present disclosure.
- FIG. 8 depicts a SYBR® Gold stained electrophoresis gel of DNA electroeluted from solid media using native gel electrophoresis in accordance with aspects of the present disclosure.
- embodiments of the invention include a method for extracting genetic material (e.g., DNA) directly from biological samples stored on a solid medium (e.g., chemically treated cellulose substrate) using electroelution.
- the method includes obtaining the solid medium that includes a stored biological sample previously applied and dried on the solid medium.
- the solid medium includes chemicals that lyse the biological sample and preserve the genetic material.
- the method also includes electroeluting the genetic material directly from the solid medium to a subsequent medium after removing the chemicals from the solid medium.
- the subsequent medium may include an electrophoresis gel, a solution, or a capture surface (e.g., a blotting membrane).
- fixed samples of cells or tissues may be applied to the solid medium.
- the fixed samples may be processed prior to or after application to the solid medium.
- processing of the fixed samples may include rehydrating and/or lyzing the fixed sample. Whether fixed or not, the samples may be further processed subsequent to application to the solid medium.
- repair of nicks and abasic sites within the genetic material may occur, while the genetic material is in a fixed position on the solid medium.
- the methods above provide a single platform for lyzing a biological sample, extracting DNA from the biological sample, binding the DNA to a surface, washing the DNA, and eluting high molecular weight (e.g., at least 10 kilobases) as wells as less fragmented DNA.
- the ability to directly electroelute the genetic material from the solid medium avoids the use of detergents normally used to extract DNA as well as the extra steps necessary to remove the detergent and make the DNA usable for subsequent analysis.
- directly electroeluting the genetic material from the solid medium without using high temperatures reduces the fragmentation of DNA.
- researchers have had to insert the solid medium on which the DNA is located directly into subsequent genetic analysis reactions (e.g. PCR) to analyze the DNA that is bound on the solid medium. It can be appreciated that elution of DNA from the solid medium allows for the evaluation of the genetic material in more than just one reaction. Overall, the disclosed embodiments reduce the work of the user in extracting the DNA from the solid medium while improving the quality and availability of the DNA.
- Biological samples used in the embodiments below may include physiological/pathological body liquids (e.g., secretions, excretions, exudates, and transudates) or cell suspensions (e.g., blood, lymph, synovial fluid, semen, saliva containing buccal cells, skin scrapings, hair root cells, etc.), liquid extracts or homogenates of cell suspensions of humans and animals; physiological/pathological liquids or cell suspensions of plants; liquid products, extracts or suspensions of bacteria, fungi, plasmids, viruses, etc.; liquid products, extracts, or suspensions of parasites including helminths, protozoas, spirochetes, etc.; human or animal body tissues (e.g., bone, liver kidney, etc.); media from DNA or RNA synthesis; mixtures of chemically or biochemically synthesized DNA or RNA; and any other source in which DNA and/or RNA is or can be in a liquid medium.
- physiological/pathological body liquids e.g
- FIG. 1 is a flow chart illustrating an embodiment of a method 10 for extracting genetic material (e.g., DNA) from a biological sample (e.g., tissues, cells, viruses, bacteriophages, or any other sample containing nucleic acid) stored on a solid medium.
- a biological sample e.g., tissues, cells, viruses, bacteriophages, or any other sample containing nucleic acid
- Processing of the biological sample may occur prior to application of the biological sample to the solid medium.
- biological samples including cells or tissues may be fixed (e.g., in formalin).
- Processing of the fixed tissue or cells may include rehydrating the fixed cells or tissues, lyzing the cells or tissues (e.g., with protease), and/or reversing cross-linking between the genetic material (e.g., DNA) and proteins. In certain embodiments, some of the processing, such as reversing cross-linking, may occur subsequent to application of the fixed cells or tissues to the solid medium.
- reversing cross-linking may occur subsequent to application of the fixed cells or tissues to the solid medium.
- the solid medium includes a chemically treated absorbent cellulose-based material.
- the solid medium may include Whatman® FTA® or FTA® Elute paper (GE Healthcare).
- the solid medium includes chemicals that lyze the biological sample (e.g., tissues or cells) and/or preserve the genetic material on the solid medium.
- the solid medium and composition of chemicals may be as described in greater detail in U.S. Pat. No. 5,976,572, entitled “Dry Solid Medium for Storage and Analysis of Genetic Material,” and U.S. Pat. No. 5,985,327, entitled “Solid Medium and Method for DNA Storage,” both of which are hereby incorporated by reference in their entirety for all purposes.
- the solid medium may include a weak base (e.g., tris-hydroxymethyl methane (tris)), chelating agent (e.g., ethylene diamine tetracetic acid (EDTA)), anionic surfactant or detergent (e.g., sodium dodecyl sulphate (SDS)), and/or uric acid or urate salt.
- a weak base e.g., tris-hydroxymethyl methane (tris)
- chelating agent e.g., ethylene diamine tetracetic acid (EDTA)
- anionic surfactant or detergent e.g., sodium dodecyl sulphate (SDS)
- SDS sodium dodecyl sulphate
- uric acid or urate salt e.g., sodium dodecyl sulphate
- the chemicals lyse the biological sample and denature proteins.
- the chemicals inactivate nucleases and pathogens to allow for the preservation and long term storage
- a portion of the solid medium containing the sample is removed for electroeluting the genetic material (e.g., DNA) from this portion (block 18).
- the entire sample may be used.
- the portion of the solid medium containing the biological sample may be rinsed to remove the chemicals (block 20).
- rinsing the portion of the sample-containing solid medium includes soaking the solid medium portion in a buffer solution or flowing buffer through or across the solid medium portion.
- the buffer solution includes an alkaline buffer solution (e.g., pH 8.0) including at least tris and EDTA (e.g., T.E.).
- the solid medium portion with the sample may be soaked one or more times for a fixed time (e.g., 5 minutes) in the alkaline buffer solution.
- the buffer solution includes Whatman® FTA® purification reagent from GE Healthcare.
- the solid medium portion with the sample may be soaked one or more times for a fixed time (e.g., 5 minutes) in the FTA® purification reagent.
- both the alkaline buffer solution and the FTA® purification reagent may be used to rinse the sample-containing solid medium portion.
- the sample-containing solid medium portion may be soaked for a fixed time (e.g., 5 minutes each soaking) twice in the alkaline buffer solution and for a fixed time (e.g., 5 minutes each soaking) twice in the FTA® purification reagent.
- rinsing the portion of the sample-containing solid medium includes soaking the solid medium portion in water or flowing water through or across the solid medium portion.
- the solid medium portion with the sample may be soaked one or more times for a fixed time (e.g., 5 minutes) in the water.
- electroelution e.g., electroelution in dialysis tubing
- rinsing of the sample-containing solid medium may not be necessary.
- the solid medium portion with the sample may be treated with enzymes (block 22) to reduce or eliminate non-DNA contaminants (e.g., proteins, lipids, carbohydrates, etc.).
- enzymes e.g., proteins, lipids, carbohydrates, etc.
- an enzymatic solution may include hydrolytic enzymes such as proteases, lipases, and/or glycoside hydrolases.
- the genetic material e.g., DNA
- the genetic material stored on the solid medium may include nicks (i.e., absence of phosphodiester bond between adjacent nucleotides) or abasic sites (also called AP sites, i.e., absence of a purine or pyrimidine base in a nucleotide while retaining the integrity of the phosphodiester ribose backbone) introduced via a fixing agent (e.g., formalin) in pre-processed samples or via other means.
- nicks i.e., absence of phosphodiester bond between adjacent nucleotides
- abasic sites also called AP sites, i.e., absence of a purine or pyrimidine base in a nucleotide while retaining the integrity of the phosphodiester ribose backbone
- a fixing agent e.g., formalin
- repairing the genetic material includes applying a solution containing at least DNA polymerase (e.g., E. coli DNA polymerase I) and DNA ligase (e.g., T4 DNA ligase or a bacterial DNA ligase) to repair the nicked damage.
- DNA polymerase e.g., E. coli DNA polymerase I
- DNA ligase e.g., T4 DNA ligase or a bacterial DNA ligase
- the DNA polymerase includes DNA polymerase activity in addition to both 3′ to 5′ exonuclease activity to mediate proofreading and 5′ to 3′ exonuclease activity to mediate nick translation during DNA repair.
- DNA polymerase requires dNTP's.
- the DNA ligase includes enzymatic activity to form a phosphodiester bond between adjacent nucleotides.
- DNA ligase requires either rATP or NAD.
- the sample-containing solid medium portion may be incubated with the DNA repair solution at 37° C. for 30 minutes, and then incubated at 65° C. for 20 minutes.
- the DNA repair solution may include other DNA repair enzymes with similar or different DNA repair mechanisms.
- AP endonuclease e.g., E. coli endonuclease IV
- the abasic site can be cleaved by an AP endonuclease, leaving 3 ′ hydroxyl and 5′ deoxyribosephosphate termini. This structure can be subsequently repaired by the combined action of DNA polymerase and DNA ligase.
- the genetic material is directly electroeluted from the solid medium to a subsequent medium (block 26).
- the sample-containing solid medium portion may be disposed directly into a well of an electrophoresis gel (e.g., agarose gel), the well sealed with agarose, and the genetic material directly electroeluted into the electrophoresis gel ( FIGS. 2 and 3 ).
- the genetic material may be electroeluted into a solution. Electroelution into a solution may occur in a variety of ways.
- D-tubeTM dialyzers (Merck Biosciences Ltd.), dialysis cassettes or tubing, Whatman® Elutrap® Electroelution Systems (GE Healthcare), or other devices may be used to electroelute the genetic material directly from the solid medium into solution.
- the genetic material may be directly electroeluted from the solid medium onto a capture surface.
- the capture surface may be on a blotting membrane (e.g., diethylaminoethyl cellulose (DEAE)).
- DEAE diethylaminoethyl cellulose
- the extracted genetic material may be analyzed (block 28).
- the genetic material extracted from the sample-containing solid medium includes high molecular weight DNA optimally of at least 10 kilobases with few nicks present. Indeed, the DNA extracted in accordance with the present approaches may approach 40 kilobases.
- DNA extraction occurs in the absence of detergents. If detergent were used in extracting the DNA from the solid medium, additional steps would typically be performed to remove the detergent before any subsequent analysis of the extracted DNA could occur.
- the extraction of DNA at high temperatures e.g., 95° C.
- the extracted DNA may be used in a variety of analyses including polymerase chain reaction (PCR), single-nucleotide polymorphism analysis, real-time PCR, and other downstream uses of the DNA.
- FIGS. 2 and 3 illustrate examples of the electroelution of DNA directly from the sample-containing solid medium into electrophoresis gels.
- FIG. 2 depicts a SYBR® Gold (Invitrogen) stained electrophoresis gel of DNA electroeluted from solid media using pulsed-field gel electrophoresis. Electrophoresis was in a 1% agarose gel, 0.5 ⁇ TE, ph 8.0 for 18 hours at 6 V/cm with a switch angle of 120° and switch time from 50-90 seconds. 20 ⁇ L of Jurkat cells (suspended at 2 ⁇ 10 6 cells/mL) were applied to either Whatman® FTA® or FTA® Elute paper and dried as described above.
- SYBR® Gold Invitrogen
- Lane 1 Saccharomyces cerevisiae chromosomal DNA size marker (BioRad); Lane 3: FTA® paper soaked for 5 minutes in TE, ph 8.0; Lane 5: FTA® paper soaked for 5 minutes in FTA® purification reagent (two times) and soaked for 5 minutes in TE buffer, ph 8.0 (two times); Lane 7: FTA® Elute paper soaked in water for 5 minutes; Lane 9: FTA® Elute paper soaked in water for 5 minutes, then vortexed for 15 seconds; Lane 11: FTA® Elute paper soaked in water for 5 minutes, then eluted into 95° C.
- Lane 12 FTA® Elute paper soaked in water for 5 minutes, then eluted into 95° C. water for 25 minutes, and vortexed for 60 seconds; and Lane 14: Saccharomyces cerevisiae chromosomal DNA size marker (BioRad). After pulsed-field gel electrophoresis, the DNA was stained with SYBR® Gold and the gel was imaged on a TyphoonTM Imager fluorescent scanner.
- FIG. 2 demonstrate the electroelution of high molecular weight DNA from the samples of Jurkat cells directly from the solid medium (i.e., FTA® or FTA® Elute paper) into the electrophoresis gel.
- the electroeluted DNA is less than 225 kilobases but estimated to be approximately 40 kilobases.
- FIG. 2 also demonstrates the absence of high molecular weight DNA when attempting to elute the DNA under high temperature conditions (e.g., 95° C.).
- a buffer solution e.g., TE buffer or FTA® purification reagent
- FIG. 3 illustrates similar results using alkaline gel electrophoresis.
- FIG. 3 depicts a SYBR® Gold stained electrophoresis gel of DNA electroeluted from solid media using alkaline standard gel electrophoresis. Electrophoresis was in a 1% agarose gel, 30 mM NaOH, 1 mM EDTA, for 2 hours at 150 mA. During electrophoresis the gel was covered in a glass plate to prevent diffusion out of the gel. As above, 20 ⁇ L of Jurkat cells (suspended at 2 ⁇ 10 6 cells/mL) were applied to Whatman® FTA® paper and dried as described above.
- the results in FIG. 3 also demonstrate the electroelution of high molecular weight DNA from the samples of Jurkat cells directly from the solid medium (i.e., FTA® or FTA® Elute paper) into the electrophoresis gel.
- the electroeluted DNA is greater than 10 kilobases.
- a buffer solution e.g., TE buffer or FTA® purification reagent
- water is needed in order to electroelute high molecular weight DNA from the solid medium directly into the electrophoresis gel.
- a buffer solution e.g., TE buffer or FTA® purification reagent
- the fact that the large DNA is also present on an alkaline gel indicates that the electroeluted DNA contains few nicks. As the DNA in an alkaline gel is single stranded, any nicks in the backbone would result in DNA fragments.
- FIG. 4 is a flow chart illustrating a method 30 for extracting genetic material (e.g., DNA) from a fixed tissue sample stored on a solid medium.
- the fixed samples may also include fixed cells (e.g., derived from tissues or cell culture lines).
- tissue is collected from a source (e.g., a mouse or human) (block 32).
- a fixing agent such as formalin, paraformaldehyde, or other fixing agent, according to methods know to the art.
- the genetic material e.g., DNA
- the fixed tissue samples may be dehydrated (block 36) in a series of ethanol washes with the ethanol sequentially increasing in concentration. The dehydrated samples may then be washed in xylene and embedded in paraffin.
- the sample is rehydrated (block 38) in a series of ethanol washes sequentially decreasing in concentration.
- the fixed tissue sample is rehydrated sequentially for 5 minutes each in 100% ethanol, 75% ethanol, 50% ethanol, 25% ethanol, and distilled water (or T.E.).
- the rehydrated sample may be incubated overnight in 1 M potassium thiocyanate.
- the fixed tissue sample, rehydrated or not, may be lyzed (block 40), e.g., with a protease, prior to application to the solid medium.
- the fixed tissue sample may be lyzed in a digest buffer solution including Proteinase K (0.5 mg/mL), 50 mM Tris at pH 7.4, 10 mM EDTA, 0.5% SDS, and 50 mM NaCl at 55° C. for at least three hours.
- the fixed tissue sample may be lysed via chemicals present on the solid medium as described above.
- the sample of fixed is applied to the solid medium via such methods as rubbing the sample against the media, pressing the sample against the media, etc.
- the solid medium is as described above.
- the solid medium includes chemicals to preserve the genetic material on the solid medium.
- the solid medium includes chemicals that lyze the fixed tissue sample as described above. Any liquid within the applied tissue sample evaporates after application. Drying of the sample on the solid medium (block 44) occurs after application.
- the solid medium containing the sample may dry overnight in a desiccator.
- the solid medium containing the sample may be encased in a protective material (e.g., a plastic film) to further preserve the genetic material.
- a portion of the solid medium containing the sample is removed for electroeluting the genetic material (e.g., DNA) from this portion.
- the entire sample may be used.
- the portion of the solid medium containing the sample may be rinsed to remove the chemicals (block 46).
- rinsing the portion of the sample-containing solid medium includes soaking the solid medium portion in a buffer solution.
- the buffer solution may include an alkaline buffer solution (e.g., TE) or FTA® purification reagent.
- the sample-containing solid medium portion may be soaked for a fixed time (e.g., 5 minutes each soaking) twice in the FTA® purification reagent and for a fixed time (e.g., 5 minutes each soaking) twice in the alkaline buffer solution.
- the rinses may occur only in the alkaline buffer solution, only in the FTA® purification reagent, or only in water as described above.
- electroelution e.g., electroelution in dialysis tubing
- rinsing of the sample-containing solid medium may not be necessary.
- the solid medium portion with the fixed sample may be treated with enzymes (block 48) to reduce or eliminate non-DNA contaminants (e.g., proteins, lipids, carbohydrates, etc.).
- enzymes e.g., proteins, lipids, carbohydrates, etc.
- an enzymatic solution may include hydrolytic enzymes such as proteases, lipases, and/or glycoside hydrolases.
- the cross-linking between the genetic material and protein may be reversed (block 50) subsequent to applying the fixed tissue sample to the solid medium.
- a crosslink repair buffer including a primary amine (e.g., bicine, pH 8.5) or other nucleophile with a pH higher than 7.0 (preferably with a pH between 7.5-10).
- the sample-containing solid medium portion is incubated in the crosslink repair buffer (e.g. at 65° C. for 20 hours).
- the primary amine or nucleophile reacts with the portion of the crosslink that comes from the aldehyde that originally formed the cross-links (between the genetic material and/or the protein) and reverses these cross-links.
- a sulfhydryl reagent can be used in place of amine, which will also react with the portion of the crosslink that is derived from the aldehyde. This reaction occurs more rapidly than amine-based nucleophile when performed at a pH below 7.
- the reversal of the cross-linking may occur prior to application of the fixed tissue sample to the solid medium. Further, prior to electroeluting genetic material from the sample-containing solid medium portion, the genetic material (e.g., DNA) may be repaired while fixed in position on the solid medium (block 52) as described above.
- the genetic material is directly electroeluted from the solid medium to a subsequent medium (block 54) as described above to obtain high molecular weight DNA of at least 10 kilobases.
- the extracted genetic material may then be analyzed (block 56) in a variety of ways (e.g., PCR) as demonstrated in FIG. 5 .
- FIG. 5 illustrates the quality of the DNA extracted from formalin-fixed tissue samples on solid media following crosslink reversal and DNA repair as described above.
- FIG. 5 depicts a SYBR® Gold stained electrophoresis gel, using a vertical polyacrylamide gel electrophoresis (PAGE) system, of multiplex PCR amplification of DNA that has been extracted from a human prostate sample fixed in formalin and applied to Whatman® FTA® paper as described above. Electrophoresis was in a 6% TBE (Tris-Borate-EDTA)-UREA gel and 1 ⁇ TBE for 40 minutes at 160V. The fixed human prostate sample was processed as described above (e.g., rehydrated or lysed) and applied to the FTA® paper.
- TBE Tris-Borate-EDTA
- the samples on the FTA® paper were then subjected to crosslink reversal and/or DNA repair (with or without endonuclease IV (Endo IV)).
- the solid media is added directly to a PCR reaction containing 3 sets of PCR primers.
- the sequences of the primers are as follows: 5′ CTCACCCTGAAGTTCTCAGG 3 ′ (primer 1), 5′ CCTCAAGGGCACCTTTGCCA 3′ (primer 2), 5′ GTCTACCCTTGGACCCAG 3′ (primer 3), and 5′ GATGAAGTTGGTGGTGAGG 3′ (primer 4).
- the PCR primers are designed to produce products of 78 base pairs (primers 1 and 2), 218 base pairs (primers 1 and 3), and 380 base pairs (primers 1 and 4) if high molecular weight human DNA is present.
- Amplification conditions were as follows: step 1: 95° C. for 7 minutes; step 2 (for 15 cycles): 95° C. for 1 minute, 69° C. for 1 minute, and 72° C. for 1 minute; step 3 (for 15 cycles): 95° C. for 1 minute, 63° C. for 1 minute, and 72° C. for 1 minute; step 4: 72° C. for 10 minutes; and then step 5: 4° C.
- the samples shown in FIG. 5 are as follows:
- Lane 1 low molecular weight DNA ladder (New England Biolabs); Lane 3: purified human DNA (Male, Applied Biosystems); Lane 4: no DNA control; Lane 5: purified human DNA treated with repair reaction (without Endo IV); Lane 6: purified human DNA treated with repair reaction (with Endo IV); Lane 8: formalin-fixed human prostate sample on FTA® paper with crosslink reversal and repair reactions (without Endo IV); Lane 9: formalin-fixed human prostate sample on FTA® paper with repair reaction only (with Endo IV); Lane 10: formalin-fixed human prostate sample on FTA® paper with crosslink reversal and repair reactions (with Endo IV); Lane 11: formalin-fixed human prostate sample on FTA® paper with repair reaction only (with Endo IV); Lane 12: formalin-fixed human prostate sample on FTA® paper with crosslink reversal reaction only; Lane 13: formalin-fixed human prostate sample on FTA® paper without crosslink reversal and repair reactions; and Lane 15: low molecular weight DNA ladder. After PAGE gel
- FIG. 5 demonstrate the appearance of the higher molecular weight PCR products (218 base pairs and 380 base pairs) when the sample on the FTA® paper has been treated to reverse cross-links and to repair DNA (Lane 10) as described above. All other combinations of treatment fail to produce these higher molecular weight PCR products. While the DNA in this experiment has not been eluted from the FTA® paper prior to PCR, it can be appreciated that if the repaired sample still located on the FTA® paper can be used for PCR amplification of higher molecular weight targets, this result in combination with the ability to elute DNA from FTA® paper would allow for a greater range of DNA interrogation experiments to be performed on such samples.
- FIGS. 6 and 7 illustrate the benefit of rehydrating fixed samples prior to electroelution from the FTA paper.
- FIGS. 6 and 7 depict a SYBR® Gold stained electrophoresis gel of DNA electroeluted from solid media using native gel electrophoresis. Electrophoresis was in a 0.8% agarose TBE gel for 80 minutes at 110 volts. The samples shown in FIG.
- Lane 1 1 kb DNA ladder (New England Biolabs); Lane 2: 0.5 mm slice of formalin-fixed human prostate sample applied directly to FTA® paper, dried, and rinsed in water and electroeluted; Lane 3: 20 ⁇ L of Jurkat cells (suspended at 2 ⁇ 10 6 cells/mL) were applied to FTA® paper, dried, and electroeluted; and Lane 4: purified human DNA (Male, Applied Biosystems). The electroeluted samples shown in FIG.
- Lane 7 are as follows: Lane 1: purified human DNA (Male, Applied Biosystems); Lane 2: 20 ⁇ L of Jurkat cells (suspended at 2 ⁇ 10 6 cells/mL) were applied to FTA® paper, and dried; Lane 3: an approximately 0.5 mm slice of formalin-fixed human prostate sample was rehydrated as described above and applied to FTA® paper, dried, and rinsed in water; and Lane 4: approximately 0.5 mm of formalin-fixed human prostate sample was scraped off the paraffin block as a series of flakes, then rehydrated as described above, applied to FTA® paper, dried, and rinsed in water. After TBE-gel electrophoresis, the DNA was stained with SYBR® Gold and the gel was imaged on a TyphoonTM Imager fluorescent scanner.
- FIGS. 6 and 7 in particular a comparison between lane 2 of FIG. 6 and lanes 3 and 4 of FIG. 7 , clearly indicate that the rehydration process aids in the retrieval of DNA from fixed samples.
- the inclusion of steps to rehydrate tissue samples that have been dehydrated in preparation for fixation and for paraffin embedding increases the yield of genetic material from the fixed sample upon electroelution.
- FIG. 8 illustrates the effect of DNA repair on the molecular weight of DNA obtained from fixed samples that have been electroeluted from FTA paper.
- FIG. 8 depicts a SYBR® Gold stained electrophoresis gel of DNA electroeluted from solid media using native gel electrophoresis. Electrophoresis was in a 0.8% agarose TBE gel for 80 minutes at 110 volts. Samples from formalin-fixed human lung (ILS 19279-A04) were applied to FTA® paper as described above. Cross-links were repaired in 100 mM bicine pH 9.5 and/or treated with a DNA repair reaction in certain samples as described above. The samples were stopped at different stages of the reactions. The samples shown in FIG. 8 are as follows:
- Lane 1 1 kb DNA ladder (New England Biolabs); Lane 2: post rehydration (i.e., ethanol and T.E. washes); Lane 3: post FTA® purification reagent washes; Lane 4: post Proteinase K digestion; Lane 5: post crosslink reversal reaction conducted at 65° C.; Lane 6: post crosslink reversal reaction conducted at room temperature; Lane 7: post DNA precipitation (plus crosslink reversal reaction conducted at 65° C.); Lane 8: post DNA precipitation (plus crosslink reversal reaction conducted at room temperature); Lane 9: post DNA repair reaction (plus crosslink reversal reaction conducted at 65° C.); and Lane 10: post DNA repair reaction (plus crosslink reversal reaction conducted at room temperature).
- FIG. 8 demonstrate the appearance of high molecular weight material in lanes 9 and 10 (indicated by the arrow) only after the DNA repair reaction has been used to repair the DNA that is still attached to the FTA® paper.
- the DNA is repaired while it is still attached to the FTA® paper, before the DNA has been subjected to the forces involved in elution of the DNA from the FTA® paper and the forces that are applied to DNA in solution.
- This prevents strands of DNA which contain nicks that are located relatively near each other, but on opposite sides, from separating. By repairing these highly nicked and gapped strands, they are prevented from becoming double stranded breaks, and the resulting product is higher molecular weight DNA.
- the increase in molecular weight provides evidence that the DNA repair reaction was able to repair nicks and gaps in the DNA.
- inventions include extracting genetic material (e.g., high molecular weight DNA of at least 10 kilobases) directly from the solid medium via electroelution.
- the extraction of genetic material occurs in the absence of detergent, thus eliminating additional steps necessary for the removal of detergent prior to any subsequent analysis of the genetic material.
- the extraction of genetic material avoids the use of high temperatures (e.g., 95° C.), thus allowing the extraction of minimally fragmented DNA.
- the extraction of genetic material, via electroelution directly from the solid medium applies to both fixed and non-fixed samples.
- the genetic material may be processed while still on the solid medium. For example, genetic material may be repaired and/or cross-links reversed in fixed cells between the genetic material and protein.
- the solid medium provides a single platform for the extraction of genetic material and related processes (e.g., DNA repair) minimizing the work for the user.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/972,236 US20120152743A1 (en) | 2010-12-17 | 2010-12-17 | Method for electroeluting genetic material from dried samples |
JP2013544728A JP6118262B2 (ja) | 2010-12-17 | 2011-12-14 | 乾燥試料から遺伝子材料を電気溶出する方法 |
PCT/US2011/064823 WO2012082849A1 (en) | 2010-12-17 | 2011-12-14 | Method for electroeluting genetic material from dried samples |
EP11848353.6A EP2652175B1 (en) | 2010-12-17 | 2011-12-14 | Method for electroeluting genetic material from dried samples |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/972,236 US20120152743A1 (en) | 2010-12-17 | 2010-12-17 | Method for electroeluting genetic material from dried samples |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120152743A1 true US20120152743A1 (en) | 2012-06-21 |
Family
ID=46232952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/972,236 Abandoned US20120152743A1 (en) | 2010-12-17 | 2010-12-17 | Method for electroeluting genetic material from dried samples |
Country Status (4)
Country | Link |
---|---|
US (1) | US20120152743A1 (ja) |
EP (1) | EP2652175B1 (ja) |
JP (1) | JP6118262B2 (ja) |
WO (1) | WO2012082849A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9040675B2 (en) | 2012-04-30 | 2015-05-26 | General Electric Company | Formulations for nucleic acid stabilization on solid substrates |
US9040679B2 (en) | 2012-04-30 | 2015-05-26 | General Electric Company | Methods and compositions for extraction and storage of nucleic acids |
US9044738B2 (en) | 2012-04-30 | 2015-06-02 | General Electric Company | Methods and compositions for extraction and storage of nucleic acids |
US9333463B2 (en) | 2013-07-26 | 2016-05-10 | General Electric Company | Devices and systems for elution of biomolecules |
US9480966B2 (en) | 2012-04-30 | 2016-11-01 | General Electric Company | Substrates and methods for collection, stabilization and elution of biomolecules |
US9999856B2 (en) | 2013-07-26 | 2018-06-19 | General Electric Company | Methods for electroelution of biomolecules |
US10638963B2 (en) | 2017-01-10 | 2020-05-05 | Drawbridge Health, Inc. | Devices, systems, and methods for sample collection |
US11266337B2 (en) | 2015-09-09 | 2022-03-08 | Drawbridge Health, Inc. | Systems, methods, and devices for sample collection, stabilization and preservation |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9399986B2 (en) | 2012-07-31 | 2016-07-26 | General Electric Company | Devices and systems for isolating biomolecules and associated methods thereof |
GB2552110B (en) * | 2012-08-30 | 2018-05-23 | Gen Electric | Methods of isolating nucleic acids under reduced degradation condition |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187083A (en) * | 1990-11-13 | 1993-02-16 | Specialty Laboratories, Inc. | Rapid purification of DNA |
US6221635B1 (en) * | 1999-05-06 | 2001-04-24 | The Wistar Institute | Methods for solid-phase amplification of DNA template (SPADT) using multiarrays |
US6277604B1 (en) * | 1994-10-28 | 2001-08-21 | Genset | Methods for solid-phase nucleic acid amplification and sequencing |
US6503716B1 (en) * | 2000-11-28 | 2003-01-07 | Pe Corporation (Ny) | Compositions and methods for extracting a nucleic acid |
US20040221332A1 (en) * | 2001-04-12 | 2004-11-04 | Rene Lorbiecke | Plant growth regulating genes, proteins and uses thereof |
US20040219545A1 (en) * | 2001-04-13 | 2004-11-04 | Rando Robert F. | Methods for identifying small molecules that bind specific rna structural motifs |
US20040235138A1 (en) * | 2003-05-19 | 2004-11-25 | Weisburg William G. | Compositions, methods and kits for determining the presence of Trichomonas vaginalis in a test sample |
US20040241734A1 (en) * | 2003-04-28 | 2004-12-02 | Exagen Diagnostics | Methods for in situ hybridization without the need for competitior DNA |
US20060088868A1 (en) * | 2004-10-21 | 2006-04-27 | New England Biolabs, Inc. | Repair of nucleic acids for improved amplification |
US20060147944A1 (en) * | 2005-01-04 | 2006-07-06 | Piotr Chomczynski | Reagents and methods for storage and processing of biological samples for DNA analysis |
US7115400B1 (en) * | 1998-09-30 | 2006-10-03 | Solexa Ltd. | Methods of nucleic acid amplification and sequencing |
US20100285578A1 (en) * | 2009-02-03 | 2010-11-11 | Network Biosystems, Inc. | Nucleic Acid Purification |
US20120109530A1 (en) * | 2005-06-16 | 2012-05-03 | Parks Patrick J | Method of classifying chemically crosslinked cellular samples using mass spectra |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4071907B2 (ja) * | 1999-11-29 | 2008-04-02 | オリンパス株式会社 | 自動核酸検査装置 |
GB0127809D0 (en) * | 2001-11-20 | 2002-01-09 | Dna Res Innovations Ltd | Purification of nucleic acid |
US20060094015A1 (en) * | 2002-10-04 | 2006-05-04 | Whatman Inc. | Methods and materials for using chemical compounds as a tool for nucleic acid storage on media of nucleic acid purification systems |
AU2003282741A1 (en) * | 2002-10-07 | 2004-05-04 | Marligen Biosciences, Inc. | Extraction of dna from biological samples |
GB0604973D0 (en) * | 2006-03-11 | 2006-04-19 | Central Science Lab Csl Of San | Purification method and kit |
-
2010
- 2010-12-17 US US12/972,236 patent/US20120152743A1/en not_active Abandoned
-
2011
- 2011-12-14 WO PCT/US2011/064823 patent/WO2012082849A1/en active Application Filing
- 2011-12-14 JP JP2013544728A patent/JP6118262B2/ja active Active
- 2011-12-14 EP EP11848353.6A patent/EP2652175B1/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187083A (en) * | 1990-11-13 | 1993-02-16 | Specialty Laboratories, Inc. | Rapid purification of DNA |
US6277604B1 (en) * | 1994-10-28 | 2001-08-21 | Genset | Methods for solid-phase nucleic acid amplification and sequencing |
US7115400B1 (en) * | 1998-09-30 | 2006-10-03 | Solexa Ltd. | Methods of nucleic acid amplification and sequencing |
US6221635B1 (en) * | 1999-05-06 | 2001-04-24 | The Wistar Institute | Methods for solid-phase amplification of DNA template (SPADT) using multiarrays |
US6503716B1 (en) * | 2000-11-28 | 2003-01-07 | Pe Corporation (Ny) | Compositions and methods for extracting a nucleic acid |
US20040221332A1 (en) * | 2001-04-12 | 2004-11-04 | Rene Lorbiecke | Plant growth regulating genes, proteins and uses thereof |
US20040219545A1 (en) * | 2001-04-13 | 2004-11-04 | Rando Robert F. | Methods for identifying small molecules that bind specific rna structural motifs |
US20040241734A1 (en) * | 2003-04-28 | 2004-12-02 | Exagen Diagnostics | Methods for in situ hybridization without the need for competitior DNA |
US20040235138A1 (en) * | 2003-05-19 | 2004-11-25 | Weisburg William G. | Compositions, methods and kits for determining the presence of Trichomonas vaginalis in a test sample |
US20060088868A1 (en) * | 2004-10-21 | 2006-04-27 | New England Biolabs, Inc. | Repair of nucleic acids for improved amplification |
US20060147944A1 (en) * | 2005-01-04 | 2006-07-06 | Piotr Chomczynski | Reagents and methods for storage and processing of biological samples for DNA analysis |
US20120109530A1 (en) * | 2005-06-16 | 2012-05-03 | Parks Patrick J | Method of classifying chemically crosslinked cellular samples using mass spectra |
US20100285578A1 (en) * | 2009-02-03 | 2010-11-11 | Network Biosystems, Inc. | Nucleic Acid Purification |
Non-Patent Citations (8)
Title |
---|
Ahokas H., Electroelution of nucleic acid in microfuge tube.Nucleic Acids Research 15(16) :6759 (1987). * |
Dobbs et al., Use of FTA gene guard filter paper for the storage and transportation of tumor cells for molecular testing. Arch. Pathol. Lab. Med.,126: 56 - 63 (2002). * |
Gilbert et al., The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when? PLOS One 2(5) : e537 (2007). * |
Hempel et al., A simple mechanical procedure to produce encapsulated cells. Nucleic Acids Research 21(8) : 4408 (1993). * |
Nuchprayoon et al., FlindersTechnology Associates (FTA) filter paper-based DNA extraction with polymerase chain reaction (PCR) for detection of Pneumocystis jirovecii from respiratory specimens of immunocompromised patients.Journal of Clinical Laboratory Analysis 21 : 382 (2007). * |
Orlandi et al., Extraction-free, filter-based template preparation for rapid and sensitive PCR detection of pathogenic parasitic protozoa. Journal of Clinical Microbiology 38(6):2271 (2000). * |
Ribot et al., Rapid Pulsed-Field Gel Electrophoresis Protocol for Subtyping of Campylobacter jejuni.Journal of Clinical Microbiology 39(5) : 1889 (2001). * |
Shi et al., DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. The Journal of Histochemistry & Cytochemistry 50(8) : 1005 (2002). * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9040675B2 (en) | 2012-04-30 | 2015-05-26 | General Electric Company | Formulations for nucleic acid stabilization on solid substrates |
US9040679B2 (en) | 2012-04-30 | 2015-05-26 | General Electric Company | Methods and compositions for extraction and storage of nucleic acids |
US9044738B2 (en) | 2012-04-30 | 2015-06-02 | General Electric Company | Methods and compositions for extraction and storage of nucleic acids |
US9480966B2 (en) | 2012-04-30 | 2016-11-01 | General Electric Company | Substrates and methods for collection, stabilization and elution of biomolecules |
US10625242B2 (en) | 2012-04-30 | 2020-04-21 | General Electric Company | Substrates and methods for collection, stabilization and elution of biomolecules |
US9333463B2 (en) | 2013-07-26 | 2016-05-10 | General Electric Company | Devices and systems for elution of biomolecules |
US9999856B2 (en) | 2013-07-26 | 2018-06-19 | General Electric Company | Methods for electroelution of biomolecules |
US11266337B2 (en) | 2015-09-09 | 2022-03-08 | Drawbridge Health, Inc. | Systems, methods, and devices for sample collection, stabilization and preservation |
US10638963B2 (en) | 2017-01-10 | 2020-05-05 | Drawbridge Health, Inc. | Devices, systems, and methods for sample collection |
US10888259B2 (en) | 2017-01-10 | 2021-01-12 | Drawbridge Health, Inc. | Cartridge assemblies for storing biological samples |
US10932710B2 (en) | 2017-01-10 | 2021-03-02 | Drawbridge Health, Inc. | Carriers for storage and transport of biological samples |
US11298060B2 (en) | 2017-01-10 | 2022-04-12 | Drawbridge Health, Inc. | Devices for collecting biological samples |
Also Published As
Publication number | Publication date |
---|---|
JP2014502495A (ja) | 2014-02-03 |
EP2652175B1 (en) | 2017-09-20 |
WO2012082849A1 (en) | 2012-06-21 |
EP2652175A4 (en) | 2014-05-21 |
EP2652175A1 (en) | 2013-10-23 |
JP6118262B2 (ja) | 2017-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2652175B1 (en) | Method for electroeluting genetic material from dried samples | |
EP3164510B1 (en) | Method for separating nucleic acids | |
JP2014502495A5 (ja) | ||
CN103097532B (zh) | 高产量分离包括小靶核酸在内的靶核酸的方法 | |
US7303876B2 (en) | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases | |
AU2001297835A1 (en) | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases | |
WO2004046305A3 (en) | Method and system for cell and/or nucleic acid molecules isolation | |
US20040126796A1 (en) | Extraction of DNA from biological samples | |
EP2794631B1 (en) | Method and apparatus for isolating nucleic acids | |
Sahajpal et al. | Development and evaluation of a novel DNA purification buffer and protocol for blood samples on FTA cards | |
CN103966205A (zh) | 从血液中提取核糖核酸的方法 | |
TWI407994B (zh) | 分離核酸的方法、試劑及套組 | |
KR20030006505A (ko) | Dna 추출용 세포 용해 버퍼 및 이를 이용한 dna추출방법 | |
AU764494B2 (en) | Product and method for separation of a sample containing multiple sources of genetic material using a solid medium | |
CN102433322A (zh) | 蜂蜜基因的提取方法 | |
EP1813938A1 (en) | Composition for an electrophoresis matrix | |
WO2016003809A1 (en) | Methods for amplifying nucleic acids on substrates | |
RU2804528C1 (ru) | Способ получения образцов геномной ДНК из клеток микроорганизмов с прочной клеточной стенкой | |
KR20120059252A (ko) | 전혈을 이용한 직접 pcr 조성물 제조방법및 이를 이용한 키트 | |
JP3724321B2 (ja) | 核酸合成法 | |
Al-Zubaidi et al. | Effects of Hair dyes on Sequence Analysis of Hair Mitochondrial DNA Hypervariable Region 1 | |
EP3619309B1 (en) | Rapid purification of high quality nucleic acids from biological samples | |
Ibrahim Al-Sammarraie et al. | Effects of Hair dyes on Sequence Analysis of Hair Mitochondrial DNA Hypervariable Region 1. | |
CN118291446A (zh) | 一种植物样本核酸提取试剂盒及其使用方法 | |
WO2023114948A3 (en) | Methods of removing embedding agents from embedded samples |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENERAL ELECTRIC COMPANY, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FINEHOUT, ERIN JEAN;NELSON, JOHN RICHARD;SPOONER, PATRICK MCCOY;REEL/FRAME:025524/0331 Effective date: 20101216 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |